Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.
Actively Recruiting
Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NNC0487-0111 for treating adults with excess body weight and type 2 diabetes. The study compares four different doses of NNC0487-0111 with a placebo, which contains no active medicine. Participants receive these treatments as weekly injections under the skin, and their group assignment is decided randomly. Participants are assigned to one of five groups four groups receive different dose levels of NNC0487-0111, and one group receives a placebo. All participants also follow a reduced-calorie diet and increase their physical activity. The injections are administered once weekly using a pre-filled pen injector to the thigh, abdomen, or upper arm. Treatment continues for 84 weeks, with ongoing monitoring. Throughout the study, participants will have their body weight, waist circumference, blood sugar control HbA1c, blood pressure, cholesterol levels, and quality of life assessed at the start and at week 84. Safety is monitored by tracking adverse events and episodes of low blood sugar up to week 88. The study lasts for about 84 weeks of treatment plus safety follow-up, and participants may undergo laboratory tests and physical exams during this time.
Actively Recruiting
Healthy Volunteer
Researchers are conducting the CARAMEL-OS observational study to develop and validate personalized artificial intelligence models for assessing cardiovascular risk in women aged 40 to 60 years during their menopausal transition. This project involves a collaboration of 25 organizations across Europe and Colombia, aiming to improve cardiovascular disease prevention by integrating multi-source data, including socioeconomic, clinical, biochemical, imaging, and novel non-invasive variables related to female-specific risk factors and menopause. The study will recruit a prospective cohort of 3,000 women from six clinical sites in four European countries and Colombia, with 500 participants contributed per site. Participants will be observed without any clinical intervention, using digital self-assessment and self-management tools, including a mobile app designed to support women during menopause. Data collected will help refine cardiovascular risk stratification models and develop new predictive tools with short-term horizons. Participants will be involved in assessments spanning 21 to 24 months depending on enrollment, during which incidence of hypertension, dyslipidaemia, diabetes mellitus, and cardiovascular disease will be recorded. Mortality related to cardiovascular events will also be tracked. The study focuses on gathering comprehensive data through questionnaires, imaging, biochemical tests, and digital monitoring to support personalized prevention strategies and advance precision medicine in womens cardiovascular health.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.